Myelosuppression is a common problem in patients undergoing chemotherapy. It includes neutropenia and low white blood cell levels. In patients undergoing leukemia treatment, white blood cell counts are routinely checked on day zero and day three after chemotherapy. In the UK, the National Trust recommends an increment of two white blood cell counts at each routine complete blood count when allocating sufficient leucocytes at the start of chemotherapy after the first day, with further dose escalation or substitution for complete white blood cell count if necessary. This might also help in prevention of febrile neutropenia, an adverse effect of chemotherapy.
This is the first analysis of the prevalence of all disease conditions in the United States as a function of sex and race. Data from a recent study show that leukemia, myeloid, acute is the most common chronic benign condition, with 9.5 million people getting this treatment a year, and 5.7 million in the 18- to 49-year-old age group. Furthermore, the prevalence of all cancer conditions is higher in the U.S. than in Europe.
Current reports of disease control are not inconsistent with our results suggesting that patients undergoing CLL-CF or CMF may, potentially, have a longer progression-free survival compared to patients receiving other therapy.
Results from a recent paper is the largest to date that describes epidemiological characteristics of acute myeloid leukaemia (AML) in children and adolescents. AML in pediatric patients has a high rate of disease-related morbidity and mortality. Younger children and adolescents present with a more aggressive disease phenotype than children and adolescents with mature leukaemias, and these younger patients also have a higher risk for relapse and death.
Leukemias are very difficult to treat because of a complicated chemotherapy regimen for the treatment of the disease. There are no curative treatments for many cancers. However, the treatments for leukemia vary depending on the type of cancer.\n
Although there were similarities in mortality risks between the disease and treatment groups, patients with AML and ALL have a more favorable long-term survival rate.
Questriq is an oral small molecule kinase inhibitor that inhibits the activity of the RET proto-oncogene and is currently under study to determine its efficacy in different types of cancer. In the context of a phase II development of the drug, we report the development of a panel of investigational assays for assessment of drug efficacy and biomarker monitoring.
This analysis adds support to the emerging role of the PI3K/AKT/mTOR pathway as a potential therapeutic target of choice for AML. A prospective study comparing patients undergoing therapy with a PI3K inhibitor with a control group is warranted to further clarify this and to increase study enrollment.
We developed a novel in vitro assay that captures the effects of RTK inhibitors in human leukemia cell lines. The effect of RTK inhibitors on cell growth and cytokine production are consistent across cell lines in the assay. In addition, we have found that cells that are dependent on the activation of a select subset of RTKs may be most sensitive to inhibition, suggesting that this type of assay can be used to guide the selection of RTK-inhibitors in pre-clinical models.
A phase 3 clinical trial of QTZS for MDS-P showed significant and durable clinical benefits and improved QOL. Data from a recent study, the objective response rate was 35%. The objective response rate for the phase 3 IMM-1 trial was 32%. QTZS was the study of choice to determine the safety and efficacy of QTZS in the treatment of acute myeloid leukemia in adults in phase 3 clinical trials. The objective response rate for the phase 3 study was 60% and the overall response rate (i.e. CR and/or PR) in patients with AML was 62%.